Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. boosted its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 419.6% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 46,202 shares of the company's stock after acquiring an additional 37,311 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in Genmab A/S were worth $905,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC boosted its holdings in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares in the last quarter. Barclays PLC boosted its holdings in Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Genmab A/S during the 4th quarter worth approximately $60,000. Aquatic Capital Management LLC purchased a new stake in shares of Genmab A/S during the 4th quarter worth approximately $114,000. Finally, Blue Trust Inc. boosted its stake in shares of Genmab A/S by 169.9% during the 1st quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock worth $145,000 after acquiring an additional 4,666 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Stock Performance

GMAB stock traded down $0.46 on Friday, reaching $21.40. The company had a trading volume of 1,247,549 shares, compared to its average volume of 1,253,561. The company's fifty day moving average is $21.04 and its 200 day moving average is $20.75. The company has a market cap of $13.73 billion, a P/E ratio of 12.16, a PEG ratio of 6.51 and a beta of 0.94. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. The company had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. On average, sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GMAB. Sanford C. Bernstein lowered Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Truist Financial boosted their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday. Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, HC Wainwright reissued a "buy" rating and set a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $37.80.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.